HUP0401301A2 - Pirrolopirimidinek, eljárás előállításukra, alkalmazásuk és a vegyületeket tartalmazó gyógyszerkészítmények - Google Patents

Pirrolopirimidinek, eljárás előállításukra, alkalmazásuk és a vegyületeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0401301A2
HUP0401301A2 HU0401301A HUP0401301A HUP0401301A2 HU P0401301 A2 HUP0401301 A2 HU P0401301A2 HU 0401301 A HU0401301 A HU 0401301A HU P0401301 A HUP0401301 A HU P0401301A HU P0401301 A2 HUP0401301 A2 HU P0401301A2
Authority
HU
Hungary
Prior art keywords
group
aryl
alkyl
heterocyclyl
cycloalkyl
Prior art date
Application number
HU0401301A
Other languages
English (en)
Inventor
Claudia Betschart
Kenji Hayakawa
Osamu Irie
Junichi Sakaki
Genji Iwasaki
René Lattmann
Martin Missbach
Naoki Teno
Original Assignee
Novartis Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag. filed Critical Novartis Ag.
Publication of HUP0401301A2 publication Critical patent/HUP0401301A2/hu
Publication of HUP0401301A3 publication Critical patent/HUP0401301A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

A jelen találmány az (I) általános képletű katepszin K inhibitorokra -amelyek képletében R hidrogénatom, -R2, -OR2 vagy -NR1R2 csoport, aholRl hidrogénatom, alkil- vagy cikloalkilcsoport, és R2 alkil- vagycikloalkilcsoport, és ahol R1 és R2 egymástól függetlenül adottesetben szubsztituált; X nitrogénatom vagy =C(Z)- csoport, ahol Zhidrogénatom, -C(O)-NR3R4, -NH-C(O)-R3, -CH2-NH-C(O)-R3, -(O)-R3, -S(O)-R3, -S(O)2-R3, -CH2-C(O)-R3, -CH2-NR3R4, -R4, -C<C-CH2-R5, N-heterociklil-, (N-heterociklil)-karbonil- vagy -C(P)=C(Q)-R4 csoport,ahol P és Q hidrogénatom, alkil- vagy arilcsoport, R3 aril-, aril-alkil-, cikloalkil-, cikloalkil-alkil-, heterociklil- vagyheterociklil-alkil-csoport, R4 hidrogénatom vagy R3; vagy R3 és R4 anitrogénatommal együtt N-heterociklilcsoportot képez; és R3 és R4adott esetben szubsztituált; R5 aril-, aril-alkil-, aril-oxi-, aroil-vagy N-heterociklilcsoport, és ahol R5 adott esetben szubsztituált,ahol R13 adott esetben szubsztituált alkil-, cikloalkil- vagycikloalkil-alkil-csoport; és R14 hidrogénatom vagy adott esetbenszubsztituált[aril-, aril-W-, aril-(alkil)-W-, cikloalkil-,cikloalkil-W-, N-heterociklil- vagy N-heterociklil-W-, ftálimidil-,hidantoinil-, oxazolidinonil- vagy 2,6-dioxo-piperazinil-csoport],ahol W oxi-, karbonil-, -NH(R6)-, -NH(R6)-C(O)-, -NH(R6)-C(O)-O-,szulfinil-, szulfonil- vagy tiocsoport; R6 hidrogénatom vagy adottesetben szubsztituált alkil-, karboxi-, acil-, karbamoil-, aril-,szulfinil- vagy szulfonilcsoport; és ahol R14 adott esetbenszubsztituált vagy gyógyászatilag elfogadható sóikra vagy észtereikre,a vegyületek előállítására, valamint a találmány szerintiinhibitoroknak olyan betegségek, illetve egészségi állapotokkezelésére vagy megelőzésére történő gyógyszerészeti felhasználásáravonatkozik, amelyekben szerepet játszik a katepszin K. Ó
HU0401301A 2001-08-30 2002-08-29 Pyrrolo pyrimidines, process for their preparation, their use and pharmaceutical compositions containing them HUP0401301A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0121033.5A GB0121033D0 (en) 2001-08-30 2001-08-30 Organic compounds
PCT/EP2002/009663 WO2003020721A1 (en) 2001-08-30 2002-08-29 Pyrrolo pyrimidines as agents for the inhibition of cystein proteases

Publications (2)

Publication Number Publication Date
HUP0401301A2 true HUP0401301A2 (hu) 2004-10-28
HUP0401301A3 HUP0401301A3 (en) 2008-03-28

Family

ID=9921234

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0401301A HUP0401301A3 (en) 2001-08-30 2002-08-29 Pyrrolo pyrimidines, process for their preparation, their use and pharmaceutical compositions containing them

Country Status (30)

Country Link
US (2) US7452886B2 (hu)
EP (1) EP1423391B8 (hu)
JP (1) JP4629334B2 (hu)
KR (1) KR100695845B1 (hu)
CN (1) CN100372849C (hu)
AR (1) AR036374A1 (hu)
AT (1) ATE326469T1 (hu)
AU (1) AU2002333760B2 (hu)
BR (1) BR0212226A (hu)
CA (1) CA2458684C (hu)
CY (1) CY1105573T1 (hu)
DE (1) DE60211530T2 (hu)
DK (1) DK1423391T3 (hu)
EC (1) ECSP044998A (hu)
ES (1) ES2262888T3 (hu)
GB (1) GB0121033D0 (hu)
HK (1) HK1072254A1 (hu)
HU (1) HUP0401301A3 (hu)
IL (3) IL160367A0 (hu)
MX (1) MXPA04001935A (hu)
MY (1) MY157368A (hu)
NO (1) NO328890B1 (hu)
NZ (1) NZ531343A (hu)
PE (1) PE20030418A1 (hu)
PL (1) PL368280A1 (hu)
PT (1) PT1423391E (hu)
RU (1) RU2331644C2 (hu)
TW (1) TWI297690B (hu)
WO (1) WO2003020721A1 (hu)
ZA (1) ZA200401042B (hu)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030144234A1 (en) * 2001-08-30 2003-07-31 Buxton Francis Paul Methods for the treatment of chronic pain and compositions therefor
SE0201980D0 (sv) * 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
GB0220187D0 (en) * 2002-08-30 2002-10-09 Novartis Ag Organic compounds
US20060046979A1 (en) 2002-09-24 2006-03-02 Foster Carolyn A Organic compounds
PE20050068A1 (es) * 2003-02-06 2005-03-11 Novartis Ag 2-cianopirrolopirimidinas como inhibidores de la catepsina s
GB0304640D0 (en) * 2003-02-28 2003-04-02 Novartis Ag Organic compounds
WO2004092169A1 (ja) * 2003-04-18 2004-10-28 Ono Pharmaceutical Co., Ltd. スピロピペリジン化合物およびその医薬用途
EP1620106A1 (en) * 2003-04-28 2006-02-01 Novartis AG Pharmaceutical composition comprising a cathepsin s inhibitor and an opioid
EP1797883A3 (en) * 2003-04-28 2007-08-01 Novartis AG Pharmaceutical composition comprising a cathepsin S inhibitor and an opioid
ATE434612T1 (de) * 2003-04-30 2009-07-15 Bayer Cropscience Ag Insektizide (dihalopropenyl)phenylalkyl substituierte dihydrobenzofuran- und dihydrobenzopyran-derivate
WO2005011703A1 (en) * 2003-08-04 2005-02-10 Akzo Nobel N.V. 2-cyano-1,3,5-triazine-4,6-diamine derivatives
CA2579609A1 (en) * 2003-09-10 2005-03-17 Virochem Pharma Inc. Spirohydantoin compounds and methods for the modulation of chemokine receptor activity
WO2005080356A1 (en) 2004-02-18 2005-09-01 Astrazeneca Ab Tetrazole compounds and their use as metabotropic glutamate receptor antagonits
US20070197510A1 (en) * 2004-03-10 2007-08-23 Kazuyuki Ohmoto Nitriles and medicinal compositions containing the same as the active ingredient
ES2251292B1 (es) * 2004-04-20 2007-07-01 Inke, S.A. Procedimiento para la obtencion de un compuesto farmaceuticamente activo y de sus intermedios de sintesis.
JP5070041B2 (ja) 2004-05-03 2012-11-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 選択的アンドローゲン受容体モジュレーター（ｓａｒｍｓ）としての新規インドール化合物
TW200614993A (en) 2004-06-11 2006-05-16 Akzo Nobel Nv 4-phenyl-pyrimidine-2-carbonitrile derivatives
WO2006022454A1 (ja) 2004-08-27 2006-03-02 Ono Pharmaceutical Co., Ltd 塩基性基を含有する化合物およびその用途
KR100651849B1 (ko) * 2005-02-01 2006-12-01 엘지전자 주식회사 세탁기
CA2617725C (en) * 2005-08-05 2012-04-03 Hybrigenics Sa Novel cysteine protease inhibitors and their therapeutic applications
CA2616479A1 (en) 2005-09-01 2007-03-08 Ares Trading S.A. Treatment of optic neuritis
TW200745055A (en) * 2005-09-23 2007-12-16 Organon Nv 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
US7326715B2 (en) 2005-09-23 2008-02-05 N.V. Organon 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
AR056720A1 (es) * 2005-10-26 2007-10-17 Smithkline Beecham Corp Compuesto de tiazol substtuido composicion farmaceuticamente que lo comprende y su uso para preparar un medicamento
ES2407115T3 (es) 2005-11-18 2013-06-11 Ono Pharmaceutical Co., Ltd. Compuesto que contiene un grupo básico y uso del mismo
CA2630492C (en) * 2005-12-05 2015-04-14 Incyte Corporation Spiro-lactam compounds
US7687515B2 (en) 2006-01-17 2010-03-30 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
US8618122B2 (en) 2006-05-16 2013-12-31 Ono Pharmaceutical Co., Ltd. Compound having acidic group which may be protected, and use thereof
CN101511802A (zh) 2006-09-13 2009-08-19 阿斯利康(瑞典)有限公司 螺唑烷酮化合物及其作为代谢型谷氨酸受体增效剂的用途
TW200911803A (en) * 2007-07-16 2009-03-16 Organon Nv 6-phenyl-1H-imidazo [4,5-c] pyridine-4-carbonitrile derivatives
US7932251B2 (en) 2007-07-16 2011-04-26 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
KR20100090777A (ko) 2007-10-19 2010-08-17 아스트라제네카 아베 대사성 글루타메이트 수용체 (ｍｇｌｕｒ)의 조절제로서의 테트라졸 유도체
KR20160131126A (ko) 2008-06-20 2016-11-15 노파르티스 아게 다발성 경화증을 치료하기 위한 소아용 조성물
US8026236B2 (en) 2009-01-16 2011-09-27 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
TW201035094A (en) 2009-01-16 2010-10-01 Organon Nv 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
ES2486715T3 (es) 2009-06-29 2014-08-19 Incyte Corporation Pirimidinonas como inhibidores de PI3K
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
JP2013516420A (ja) 2009-12-30 2013-05-13 アークル インコーポレイテッド 置換されたピロロ−アミノピリミジン化合物
WO2011086125A1 (en) 2010-01-15 2011-07-21 N.V. Organon 1H-[1,2,3]TRIAZOLO[4,5-c]PYRIDINE-4-CARBONITRILE DERIVATIVES
JP5816678B2 (ja) 2010-04-14 2015-11-18 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ ＰＩ３Ｋδ阻害剤としての縮合誘導体
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
WO2012027495A1 (en) 2010-08-27 2012-03-01 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
ES2721639T3 (es) 2010-10-06 2019-08-02 Inst Catalana Recerca Estudis Avancats Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama
EP2655374B1 (en) 2010-12-20 2019-10-23 Incyte Holdings Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
LT2751109T (lt) 2011-09-02 2017-02-27 Incyte Holdings Corporation Heterociklilaminai kaip pi3k inhibitoriai
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
JP6172143B2 (ja) * 2012-04-17 2017-08-02 アステラス製薬株式会社 含窒素二環式芳香族へテロ環化合物
JP6386450B2 (ja) 2012-06-06 2018-09-05 フンダシオ、インスティトゥト、デ、レセルカ、ビオメディカ（イエレベ、バルセロナ）Ｆｕｎｄａｃｉｏ Ｉｎｓｔｉｔｕｔ Ｄｅ Ｒｅｃｅｒｃａ Ｂｉｏｍｅｄｉｃａ （Ｉｒｂ Ｂａｒｃｅｌｏｎａ） 肺がん転移の診断、予後診断および処置のための方法
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
CA2888122A1 (en) 2012-10-12 2014-04-17 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-maf
WO2014184679A2 (en) 2013-03-15 2014-11-20 Inbiomotion S.L. Method for the prognosis and treatment of renal cell carcinoma metastasis
KR20150122731A (ko) 2013-03-15 2015-11-02 펀다시오 인스티튜트 드 르세르카 바이오메디카 (아이알비 바르셀로나) 암 전이의 예후 및 치료 방법
DK3055429T3 (en) 2013-10-09 2019-04-23 Fundacio Inst De Recerca Biomedica Irb Barcelona Procedure for the prognosis and treatment of metastatic bone cancer resulting from breast cancer
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
EP3229909B1 (en) 2014-12-11 2020-10-14 Inbiomotion S.L. Binding members for human c-maf
BR122021004509B1 (pt) 2015-02-27 2023-11-07 Incyte Holdings Corporation Sais de inibidor de pi3k e processos para seu preparo
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
AU2017271385B2 (en) 2016-05-25 2023-10-05 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-MAF status
WO2019102380A1 (en) 2017-11-22 2019-05-31 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf
KR102054910B1 (ko) * 2017-12-19 2019-12-12 한림제약(주) 피롤로[2,3-d]피리미딘 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
CN112312904A (zh) 2018-04-16 2021-02-02 C4医药公司 螺环化合物
EP3556760A1 (en) * 2018-04-19 2019-10-23 F. Hoffmann-La Roche AG Spiro compounds
WO2020201572A1 (en) 2019-04-05 2020-10-08 Université De Bretagne Occidentale Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning
EP4326721A1 (en) * 2021-04-22 2024-02-28 Protego Biopharma, Inc. Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1251074B (de) * 1960-11-02 1967-09-28 J R Geigy A -G , Basel (Schweiz) Selektives Herbizid
CH627919A5 (de) 1977-04-14 1982-02-15 Ciba Geigy Ag Herbizide mittel.
US5958930A (en) * 1991-04-08 1999-09-28 Duquesne University Of The Holy Ghost Pyrrolo pyrimidine and furo pyrimidine derivatives
DE59500788D1 (de) * 1994-05-03 1997-11-20 Ciba Geigy Ag Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
US5683999A (en) * 1995-03-17 1997-11-04 The Dupont Merck Pharmaceutical Company Cyclic urea HIV protease inhibitors
JP2001516353A (ja) * 1997-03-19 2001-09-25 ビーエーエスエフ アクチェンゲゼルシャフト ピロロ［２，３ｄ］ピリミジンおよびチロシンキナーゼ阻害剤としてのこれらの使用
AU4710699A (en) * 1998-06-30 2000-01-17 Eli Lilly And Company Bicyclic sPLA2 inhibitors
ID29028A (id) * 1998-09-18 2001-07-26 Basf Ag Pirolopirimidina sebagai penghambat protein kinase
AU777911B2 (en) * 1999-12-10 2004-11-04 Pfizer Products Inc. Pyrrolo(2,3-d)pyrimidine compounds
WO2001070743A1 (en) * 2000-03-20 2001-09-27 Axys Pharmaceuticals, Inc. Non-amidine containing protease inhibitors
MXPA02010693A (es) 2000-04-28 2003-03-10 Tanabe Seiyaku Co Compuestos ciclicos.

Also Published As

Publication number Publication date
IL198643A (en) 2010-12-30
NO20041180L (no) 2004-03-19
MY157368A (en) 2016-06-15
WO2003020721A1 (en) 2003-03-13
MXPA04001935A (es) 2004-06-15
EP1423391B1 (en) 2006-05-17
IL160367A (en) 2009-12-24
CY1105573T1 (el) 2010-07-28
IL160367A0 (en) 2004-07-25
EP1423391B8 (en) 2007-12-12
AU2002333760B2 (en) 2007-01-04
DE60211530T2 (de) 2006-12-21
RU2331644C2 (ru) 2008-08-20
JP4629334B2 (ja) 2011-02-09
PT1423391E (pt) 2006-09-29
NZ531343A (en) 2006-01-27
PL368280A1 (en) 2005-03-21
CA2458684A1 (en) 2003-03-13
BR0212226A (pt) 2004-08-17
NO328890B1 (no) 2010-06-07
JP2005502683A (ja) 2005-01-27
RU2004109815A (ru) 2005-10-20
CN100372849C (zh) 2008-03-05
AR036374A1 (es) 2004-09-01
HK1072254A1 (en) 2005-08-19
CN1549817A (zh) 2004-11-24
ATE326469T1 (de) 2006-06-15
ZA200401042B (en) 2004-10-25
HUP0401301A3 (en) 2008-03-28
US7452886B2 (en) 2008-11-18
ECSP044998A (es) 2004-04-28
TWI297690B (en) 2008-06-11
KR20040029123A (ko) 2004-04-03
ES2262888T3 (es) 2006-12-01
DE60211530D1 (de) 2006-06-22
US20090054467A1 (en) 2009-02-26
GB0121033D0 (en) 2001-10-24
PE20030418A1 (es) 2003-06-12
DK1423391T3 (da) 2006-09-25
US20050054851A1 (en) 2005-03-10
KR100695845B1 (ko) 2007-03-20
CA2458684C (en) 2009-04-07
EP1423391A1 (en) 2004-06-02

Similar Documents

Publication Publication Date Title
HUP0401301A2 (hu) Pirrolopirimidinek, eljárás előállításukra, alkalmazásuk és a vegyületeket tartalmazó gyógyszerkészítmények
CN107820498B (zh) 用于治疗和预防病毒感染的取代的氨基噻唑并嘧啶二酮
MXPA04005444A (es) Ureas de 2-aminobenzotiazoles como moduladores de adenosina.
HUP0303808A2 (hu) Kondenzált biciklusos vagy triciklusos aminosavak, aljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
ES2305310T3 (es) Compuestos de pirazolidinona como ligandos de los receptores de ep2 y/o ep4 de prostaglandinas.
TWI225864B (en) Amino acids with affinity for the alpha2delta-protein
HUP0400732A2 (hu) Gyógyászatilag hatékony uridin-észterek
AU2002359164A8 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer&#39;s disease and conditions associated with glycogen synthase kinase-3
MY129422A (en) Medicinal compounds
CA2312885A1 (en) 2-aryl-8-oxodihydropurine derivatives, process for producing the same, medicinal compositions containing the same, and intermediates thereof
HUP0400607A2 (hu) Orális szabályozott hatóanyag-leadású készítmény szív- és keringési betegségek napi egyszeri gyógyszerezéssel való kezelésére és megelőzésére
MXPA01006474A (es) Derivados colquinol como agentes perjudiciales vasculares.
MXPA04005376A (es) Composiciones farmaceuticas y sus usos.
HUP0001849A2 (hu) S-Omeprazol új formája
PL341291A1 (en) 1-substituted derivatives of 1-aminomethyl-ccycloalkanes (gabapentin analogues), their production and application of them in treating neurological disorders
HUP0401250A2 (hu) Aeroszol formájú gyógyászati készítmények és eljárás az előállításukra
SI1002792T1 (en) 2-aminopropane-1,3-diol compounds, medicinal use thereof, and intermediates in synthesizing the same
CA2509413A1 (en) Benzazepine derivatives for the treatment of neurological disorders
HUP0201213A2 (hu) VLA-4-el összefüggő betegségek kezelésére szolgáló pirimidinil-, pirazinil- és tiadiazolil-fenilalanin-származékok és ezeket tartalmazó gyógyszerkészítmények
HUP0203238A2 (hu) Hatóanyagok rosszindulatú daganatok kezelésére, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
IL164225A (en) Derivatives of benzensulfonyl - methyl - amino-pyrimidin - 4 - ylamino, pharmaceutical compositions comprising them and their use for the manufacture of medicaments for treating diseases mediated by alpha 4 integrin and a process for their preparation
HUP9800719A2 (hu) N-helyettesített azaheterociklusos karboxilsavak és észtereik, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
AU2002359162A1 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer&#39;s disease and conditions associated with glycogen synthase kinase-3
PL1697394T3 (pl) Inhibitory COMT
TW200922587A (en) Alkylthio pyrimidines as CRTH2 antagonists

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees